111, Inc. (YI) 주식 분석

회사 개요

111, Inc. operates as an integrated online and offline platform within the healthcare market of the People's Republic of China, serving both B2C and B2B segments through supply chain integration services for pharmaceutical companies. The company is categorized under the Healthcare sector and specifically within the Medical Distribution industry, indicating its role as a critical intermediary in the supply chain for medical products. With a market capitalization of $56.16M and total employees numbering 1238, the firm represents a mid-sized entity in its respective niche. The annual revenue of $13.58B highlights a significant operational scale, suggesting that despite its relatively modest market cap, the company manages substantial transaction volumes that characterize its position as a major distributor in the Chinese pharmaceutical landscape.

재무 건전성

The company reported revenue of $13.58B for the trailing twelve months, yet recorded a net income of -$70,012,000 and an EBITDA of $3.98M, revealing a cost structure where operating expenses significantly erode profitability despite high sales volume. The free cash flow stands at -$22,583,250, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund growth without external capital or operational improvements. Analysis of the three key margins shows a gross margin of 2.8%, an operating margin of -0.1%, and a profit margin of -0.5%, all of which point to an extremely thin profit environment where high fixed costs or aggressive pricing strategies are suppressing returns. On the balance sheet, the company holds $493.62M in cash against $204.73M in debt, resulting in a debt-to-equity ratio of 93.56, which suggests a highly leveraged position relative to its equity base despite the substantial cash reserve. The current ratio of 1.07 indicates that the company's current assets barely exceed its current liabilities, signaling tight short-term liquidity conditions that leave little room for error in meeting upcoming obligations. Furthermore, the return on equity is -10.9% and the return on assets is -0.2%, metrics that reveal that management has not yet generated positive returns on the capital invested or deployed, reflecting ongoing operational challenges in translating revenue into shareholder value.

밸류에이션 평가

The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E stands at 46.29, implying that the market is pricing in a significant expected recovery or turnaround in earnings over the coming year. The price-to-book ratio is -0.57, which indicates that the company trades below its book value, a situation often seen in distressed firms or those with significant intangible assets not captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 0.00 and an EV/EBITDA of 437.63 suggest extreme valuation multiples driven by the lack of current profitability, making traditional comparables difficult to apply. The stock has traded between a 52-week high of $11.17 and a 52-week low of $2.48, and without a specific current price provided in the facts, the valuation context is strictly defined by this wide trading range which reflects high investor uncertainty. The beta of 0.70 indicates that the stock price is less volatile than the broader market, suggesting that while the fundamentals are distressed, the stock price movement has historically been dampened relative to general market fluctuations.

Growth & Income

Revenue growth year-over-year stands at -16.7%, while earnings growth is listed as N/A due to the negative earnings, implying that the company is currently in a contraction phase rather than a growth phase. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, meaning it must reinvest all available resources or utilize existing cash reserves to sustain operations and potentially fund future strategic initiatives. The overall growth and income profile is characterized by significant revenue contraction, negative profitability, and a complete absence of dividend income, reflecting a business currently focused on survival and operational restructuring rather than shareholder distribution or consistent top-line expansion.